Free Trial

Vericel (VCEL) Competitors

Vericel logo
$52.00 -2.31 (-4.25%)
Closing price 04:00 PM Eastern
Extended Trading
$52.00 +0.01 (+0.01%)
As of 06:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VCEL vs. PCVX, SRPT, QGEN, ASND, ROIV, RVMD, LEGN, BBIO, AXSM, and BPMC

Should you be buying Vericel stock or one of its competitors? The main competitors of Vericel include Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry.

Vericel vs.

Vaxcyte (NASDAQ:PCVX) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, community ranking, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Vaxcyte has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Vericel has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500.

Vericel has a net margin of 1.56% compared to Vaxcyte's net margin of 0.00%. Vericel's return on equity of 1.48% beat Vaxcyte's return on equity.

Company Net Margins Return on Equity Return on Assets
VaxcyteN/A -23.53% -22.20%
Vericel 1.56%1.48%0.96%

Vaxcyte currently has a consensus target price of $127.71, suggesting a potential upside of 60.16%. Vericel has a consensus target price of $63.14, suggesting a potential upside of 21.43%. Given Vaxcyte's higher possible upside, equities analysts clearly believe Vaxcyte is more favorable than Vericel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaxcyte
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00
Vericel
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Vericel has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A-$402.27M-$4.60-17.33
Vericel$197.52M12.99-$3.18M$0.06866.81

96.8% of Vaxcyte shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by company insiders. Comparatively, 5.2% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Vaxcyte and Vaxcyte both had 7 articles in the media. Vericel's average media sentiment score of 1.40 beat Vaxcyte's score of 1.08 indicating that Vericel is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vaxcyte
5 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Vericel
6 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Vericel received 306 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 75.41% of users gave Vaxcyte an outperform vote while only 61.86% of users gave Vericel an outperform vote.

CompanyUnderperformOutperform
VaxcyteOutperform Votes
46
75.41%
Underperform Votes
15
24.59%
VericelOutperform Votes
352
61.86%
Underperform Votes
217
38.14%

Summary

Vericel beats Vaxcyte on 11 of the 15 factors compared between the two stocks.

Get Vericel News Delivered to You Automatically

Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VCEL vs. The Competition

MetricVericelBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$2.57B$3.12B$5.80B$8.94B
Dividend YieldN/A1.57%4.78%3.85%
P/E Ratio867.2430.1226.4118.84
Price / Sales13.00320.52450.1476.68
Price / Cash3,278.86183.5344.0437.47
Price / Book11.003.567.634.64
Net Income-$3.18M-$71.72M$3.18B$245.69M
7 Day Performance-8.87%-2.45%-1.82%-2.59%
1 Month Performance-12.65%0.36%0.22%-2.30%
1 Year Performance8.09%-11.49%17.25%13.71%

Vericel Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VCEL
Vericel
2.9323 of 5 stars
$52.00
-4.3%
$63.14
+21.4%
+9.7%$2.57B$197.52M866.81300Positive News
PCVX
Vaxcyte
2.5867 of 5 stars
$84.00
+0.2%
$127.71
+52.0%
+11.3%$10.47BN/A-18.26160Insider Trade
Positive News
SRPT
Sarepta Therapeutics
4.4962 of 5 stars
$107.95
-1.4%
$176.77
+63.8%
-20.4%$10.31B$1.24B86.361,314Upcoming Earnings
QGEN
Qiagen
4.4279 of 5 stars
$39.85
-0.5%
$48.78
+22.4%
-7.3%$8.84B$1.98B110.975,967Analyst Downgrade
ASND
Ascendis Pharma A/S
3.1758 of 5 stars
$144.08
+1.1%
$193.43
+34.3%
-1.4%$8.74B$288.08M-17.83640Analyst Forecast
ROIV
Roivant Sciences
2.7251 of 5 stars
$10.56
+1.1%
$18.08
+71.2%
-7.1%$7.69B$122.59M1.87860Insider Trade
RVMD
Revolution Medicines
4.5108 of 5 stars
$40.67
-1.6%
$66.25
+62.9%
+44.9%$6.84B$11.58M-11.33250
LEGN
Legend Biotech
2.5939 of 5 stars
$36.42
+0.1%
$79.50
+118.3%
-35.2%$6.65B$285.14M-38.341,800Positive News
BBIO
BridgeBio Pharma
4.7193 of 5 stars
$34.90
+10.6%
$49.08
+40.6%
+2.4%$6.60B$9.30M-14.48400Earnings Report
Analyst Forecast
Insider Trade
News Coverage
Gap Up
AXSM
Axsome Therapeutics
4.5264 of 5 stars
$131.15
-0.4%
$147.13
+12.2%
+59.2%$6.36B$270.60M-20.08380Earnings Report
Analyst Forecast
Analyst Revision
News Coverage
BPMC
Blueprint Medicines
2.9925 of 5 stars
$93.94
-1.3%
$123.83
+31.8%
+3.4%$5.97B$249.38M-44.52640Earnings Report

Related Companies and Tools


This page (NASDAQ:VCEL) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners